Nevertheless, the efficacy of our pipeline is illustrated by its ability to capture the molecular targets for current HNSCC drugs including cetuximab, taxanes, and 5‐fluorouracil as well as genes for other well‐studied targets in HNSCC including other ErbB family members and PIK3CA. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.